The research team synthesized comparative observational studies that directly contrasted patients with and without previous abdominal surgery who underwent minimally invasive gastrectomy for gastric cancer. Searching four databases from their inception through February 18, 2026, the investigators identified six studies comprising seven comparative cohorts and up to 1,851 patients. The primary outcome of interest was overall postoperative complications, while secondary outcomes included conversion to open surgery, operative time, intraoperative blood loss, lymph node yield, and postoperative length of stay. Because randomized trials are neither practical nor ethical in this context, the meta-analysis of observational evidence represents the strongest available tool for quantifying how surgical history shapes perioperative outcomes, pooling odds ratios and mean differences with 95 percent confidence intervals under random-effects models to accommodate the inevitable statistical heterogeneity between studies.

The headline result concerns time on the operating table. Patients with previous abdominal surgery experienced an average of 11.17 additional minutes of operative time, with a 95 percent confidence interval spanning 3.80 to 18.54 minutes, a statistically significant difference. For an experienced surgical team, eleven minutes is not a trivial addition, since it reflects real technical work, likely the careful adhesiolysis needed to free the abdominal wall and operative field from scar tissue before the gastrectomy itself can proceed. Every additional minute under anesthesia and pneumoperitoneum carries a marginal physiological cost, and prolonged operative times are consistently associated with higher rates of surgical site infection and other complications in the broader surgical literature, making this finding clinically meaningful even though it is numerically modest.

Alongside the longer operations, the analysis detected a statistically significant but strikingly small increase in postoperative hospital stay, with a mean difference of just 0.07 days, at 95 percent confidence interval of 0.01 to 0.14 days. Expressed plainly, that is roughly one hundred minutes of additional hospitalization on average, a margin so slim that most clinicians would regard it as clinically negligible. The precision of this estimate, narrow enough to exclude the possibility of no difference, actually strengthens the reassuring interpretation: the systematic review found no evidence that prior surgery meaningfully delays recovery or discharge. In the context of enhanced recovery after surgery pathways, which have dramatically shortened gastric cancer hospitalization in many centers, this result suggests that a history of prior abdominal operations need not disqualify patients from such protocols.

On the outcomes that matter most to patient safety, the picture becomes more nuanced. Overall postoperative complications showed an odds ratio of 1.21 with a 95 percent confidence interval of 0.95 to 1.55, and conversion to open surgery showed an odds ratio of 1.75 with a confidence interval of 0.80 to 3.81. Neither result reached statistical significance, meaning the observed differences are compatible with chance. However, the authors were careful to note that clinically important increases in these risks could not be excluded. The confidence interval for complications brushes against a 55 percent relative increase at its upper bound, and the conversion confidence interval is wide enough to encompass everything from a substantial protective effect to a nearly fourfold increase in risk. This statistical ambiguity is not a weakness unique to this study; it is the honest consequence of pooling relatively few cohorts with limited event rates, and it defines the frontier of what current evidence can and cannot tell surgeons.

Encouragingly, two markers of oncological and technical quality showed no significant differences between the groups. Intraoperative blood loss and lymph node yield, the number of lymph nodes retrieved for pathological staging, were statistically indistinguishable between patients with and without previous surgery. Lymph node yield deserves particular emphasis in gastric cancer surgery, because adequate lymphadenectomy is fundamental to accurate staging and to the curative intent of gastrectomy. If adhesions and altered anatomy compromised the thoroughness of the dissection, one would expect to see reduced nodal harvests; the absence of such a difference suggests that skilled minimally invasive surgeons can navigate scarred abdomens without sacrificing oncological quality. Similarly, equivalent blood loss indicates that adhesiolysis does not translate into meaningful hemorrhagic risk in experienced hands.

Methodologically, the study adhered to established standards for evidence synthesis. The team followed PRISMA reporting guidelines and assessed risk of bias using ROBINS-E, the Risk Of Bias In Non-randomized Studies of Exposures tool, which is specifically designed to evaluate observational comparative studies rather than borrowing instruments intended for randomized trials. This choice reflects a maturing meta-analytic practice: since the exposure in question, previous abdominal surgery, cannot be randomized, the validity of conclusions rests on transparent assessment of confounding, selection bias, and measurement error in the underlying cohorts. The inclusion criteria also demanded genuine comparative designs, excluding single-arm case series that would inflate apparent safety by omitting an appropriate control group.

The clinical implications radiate outward from the operating theater to the multidisciplinary tumor board. Gastric cancer is among the leading causes of cancer mortality worldwide, and minimally invasive gastrectomy, whether laparoscopy-assisted distal or total gastrectomy, has become the standard of care at high-volume centers, offering patients less pain, faster recovery, and fewer wound complications than open surgery. A large fraction of gastric cancer patients, particularly in East Asian populations where screening detects tumors in older adults, carry surgical histories that include appendectomy, cholecystectomy, cesarean section, or prior colorectal procedures. The new evidence indicates that such histories should inform, rather than forbid, a minimally invasive approach. As the authors conclude, the findings highlight the need for individualized surgical planning, in which the type, location, and recency of prior operations, along with surgeon experience, shape the operative strategy.

Several important limitations temper the strength of the conclusions and point toward future research. The pooled analysis rests on only six studies and seven cohorts, so the estimates carry wide uncertainty, especially for the rarer outcomes such as conversion. Observational studies inherently cannot exclude residual confounding; patients with prior surgery may differ systematically in body mass index, tumor stage, comorbidity burden, or institutional referral patterns in ways the original studies did not fully adjust. Heterogeneity in the definition of previous abdominal surgery, whether limited to upper abdominal procedures or inclusive of all laparotomies and laparoscopies, may also blur true subgroup effects, since lower abdominal scar tissue is generally less disruptive to gastric mobilization than adhesions in the upper abdomen. Future studies stratifying by the anatomical site of prior surgery, and by surgeon volume, would sharpen the clinical calculus considerably.

For now, the message to patients is broadly reassuring. A history of previous abdominal surgery will make a minimally invasive gastrectomy take a few minutes longer and may, in unresolved ways, modestly influence complication and conversion risks, but it does not appear to undermine the essential quality of cancer surgery or materially delay recovery. The study, which received no specific grant funding and declared no competing interests, was published open access on October 13, 2026, under a Creative Commons license, allowing clinicians worldwide to weigh its evidence directly. As minimally invasive techniques continue to expand across surgical oncology, this synthesis offers a data-driven foundation for the conversations surgeons must have with every scarred abdomen on the operating table: informed, quantified, and centered on individualized care rather than blanket exclusion.

Subject of Research: Perioperative outcomes of minimally invasive gastrectomy for gastric cancer in patients with previous abdominal surgery

Article Title: Impact of previous abdominal surgery on perioperative outcomes after minimally invasive gastrectomy for gastric cancer: an evidence synthesis and quantitative analysis

Article References: Yue, Q., Huang, Y., Yu, R.-X., Li, K.-Q., Fu, D.-H., Wang, L., Shi, Y.-Y., & Luo, Y. (2026). Impact of previous abdominal surgery on perioperative outcomes after minimally invasive gastrectomy for gastric cancer: an evidence synthesis and quantitative analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-17123-7

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17123-7

Keywords: gastric cancer, minimally invasive gastrectomy, previous abdominal surgery, meta-analysis, postoperative complications, surgical adhesions, lymph node yield, conversion to open surgery, operative time, surgical oncology, Impact, previous

The retrospective cohort study analyzed data from 195 colorectal cancer patients who underwent curative surgery following neoadjuvant immune checkpoint inhibitor therapy. The researchers, led by Bo Liu and Bo Li with corresponding authors Jinzhu Zhang, Xueqiang Jian and Zhanlun Liu, examined the relationship between lymph node yield, the total number of lymph nodes retrieved and examined by the pathologist after surgery, and postoperative recurrence. Their central finding was striking: patients with a lymph node yield of twenty or more nodes had significantly poorer recurrence-free survival than patients with lower yields. This association persisted across subgroup analyses stratified by pathological tumor stage, microsatellite status, the type of immune checkpoint inhibitor used, and the neoadjuvant treatment strategy, indicating that the signal was not confined to a narrow slice of the patient population.

To understand why this finding matters, it helps to consider the biology of tumor-draining lymph nodes. These are the lymph nodes that receive drainage from the tumor site, and they are far more than passive filters. They are active immunological hubs where dendritic cells present tumor antigens to naive T cells, where anti-tumor immune responses are primed, and where the immune system mounts its organized defense against cancer. Immune checkpoint inhibitors, drugs that unleash T cells by blocking inhibitory receptors such as PD-1, depend heavily on this lymph node machinery. In many cancers, the response to checkpoint blockade is initiated in the tumor-draining lymph nodes, where T cells are activated and then traffic to the tumor to do their work. Removing these nodes, therefore, might not be an immunologically neutral act.

The study’s single-cell analysis adds a fascinating layer to the story. The researchers performed single-cell RNA sequencing and T-cell receptor sequencing on tumor tissue, peripheral blood, and tumor-draining lymph node samples from colorectal cancer patients. This allowed them to track individual immune cells and, crucially, to identify which T cells in the tumor were clonally related to T cells in the lymph nodes, meaning they shared identical T-cell receptor sequences and therefore descended from the same activated precursor cells. What they found was that patients treated with immune checkpoint inhibitors exhibited a higher frequency of clonally shared CD8-positive effector memory T cells between the tumor-draining lymph nodes and the tumor tissue itself.

This clonal sharing is direct evidence of immunological connectivity between the lymph nodes and the tumor. It suggests that T cells activated in the tumor-draining lymph nodes, under the stimulus of checkpoint blockade, are physically migrating to the tumor and participating in the anti-cancer attack. In other words, the lymph nodes are not just staging grounds for the immune response; they are functioning as the factories that produce the tumor-fighting T cell army that immunotherapy mobilizes. When surgeons remove twenty or more of these nodes, they may be inadvertently dismantling a critical component of the patient’s own anti-tumor immune infrastructure at precisely the moment when immunotherapy has primed it for action.

The clinical implications are potentially significant, though the researchers are careful to note the limits of what their study can establish. As a retrospective cohort study, it demonstrates association rather than causation. It is possible that higher lymph node yield is a marker of more extensive disease or more aggressive surgical practice rather than a direct cause of recurrence. Patients with more nodes removed may have had more advanced disease that prompted wider dissections, or surgeons who remove more nodes may differ systematically in ways that affect outcomes. The authors themselves acknowledge that the mechanisms underlying the association remain unclear and warrant further investigation. Nevertheless, the consistency of the finding across multiple subgroup analyses, and its alignment with a plausible biological mechanism supported by the single-cell data, gives the result a credibility that demands attention.

The finding also sits within a broader and sometimes contentious debate in surgical oncology about the optimal extent of lymphadenectomy. In colorectal cancer, guidelines typically recommend examining at least twelve lymph nodes to ensure accurate staging, since understaging can lead to inadequate adjuvant treatment decisions. Lymph node yield has historically been used as a quality metric for both surgery and pathology, with higher yields generally interpreted as evidence of more thorough cancer care. The new study does not necessarily overturn that logic for patients who do not receive neoadjuvant immunotherapy, but it raises the provocative possibility that the optimal surgical strategy may differ depending on whether a patient’s immune system has been pharmacologically primed before the operation.

Neoadjuvant immunotherapy itself is a rapidly expanding approach in colorectal cancer, particularly for patients with mismatch repair-deficient or microsatellite instability-high tumors, which are exquisitely sensitive to checkpoint blockade. In these patients, preoperative immunotherapy can produce pathological complete responses, allowing some to avoid radical surgery altogether. As the use of neoadjuvant immunotherapy grows, questions about how to adapt standard surgical techniques become increasingly urgent. If tumor-draining lymph nodes are essential partners in the immunotherapy response, as this study’s single-cell data suggest, then the standard practice of extensive lymph node dissection may need to be re-evaluated in this specific patient population, balancing the staging benefits of node removal against the potential immunological cost.

The study also highlights the power of single-cell technologies to illuminate questions that traditional pathology cannot answer. By combining T-cell receptor sequencing across multiple tissue compartments, the researchers were able to visualize the traffic of immune cells between lymph nodes and tumors in a way that would have been impossible a decade ago. This kind of integrative analysis, linking clinical outcomes with high-resolution immune profiling, represents a model for how surgical oncology questions may be addressed in the future. Rather than asking simply how many nodes to remove, surgeons and oncologists may increasingly ask what immunological functions those nodes are performing and how to preserve them.

For now, the study’s authors urge caution rather than immediate changes to practice. The association between higher lymph node yield and poorer recurrence-free survival in immunotherapy-treated colorectal cancer patients is a hypothesis-generating finding, one that should prompt prospective studies designed to test whether more conservative lymph node management could safely improve outcomes. If those studies confirm the retrospective signal, the implications would extend beyond colorectal cancer to any malignancy treated with neoadjuvant immunotherapy and surgery. What is clear already is that the era of immunotherapy is forcing a re-examination of long-held surgical dogmas, and the humble lymph node, once viewed merely as a structure to be counted and cleared, is emerging as an active and potentially indispensable ally in the fight against cancer.

Subject of Research: The association between lymph node yield and recurrence-free survival in colorectal cancer patients treated with neoadjuvant immune checkpoint inhibitor therapy

Article Title: Higher lymph node yield is associated with increased postoperative recurrence in colorectal cancer treated with neoadjuvant immunotherapy: a retrospective cohort study

Article References: Liu, B., Li, B., Zhang, J., Jian, X., & Liu, Z. (2026). Higher lymph node yield is associated with increased postoperative recurrence in colorectal cancer treated with neoadjuvant immunotherapy: a retrospective cohort study. BMC Cancer. https://doi.org/10.1186/s12885-026-16966-4

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16966-4

Keywords: colorectal cancer, immune checkpoint inhibitors, neoadjuvant immunotherapy, tumor-draining lymph nodes, lymph node yield, recurrence-free survival, single-cell RNA sequencing, T-cell receptor sequencing, CD8 T cells, lymphadenectomy, surgical oncology, tumor immunology